Recent Finacing
Recent Raise
LAVA Therapeutics develops bispecific antibodies engaging Vγ9Vδ2 gamma‑delta T cells to redirect them to tumor antigens in hematologic and solid malignancies, with R&D in Utrecht and Philadelphia.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Lava Therapeutics.
